how many people in us are on glp 1 Products - Data Briefs - Number 537 Poll: 1 in 8 Adults
Description
(2024, December 15)
Both medications contain the same active ingredient but are approved for different primary indications and at different doses
Report any unexplained fatigue, dizziness, or rapid heartbeat to your healthcare team, though these reactions are uncommon with semaglutide specifically
In its pivotal Phase 3 ATTAIN-1 trial, which involved over 3,000 adults with obesity or overweight, orforglipron demonstrated significantly higher weight loss compared to a placebo
Tirzepatide and the new oral Foundayo (orforglipron) currently dominate the weekly and oral tiers
